Andrés F. Cardona

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Alectinib in Resected <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn et al. · New England Journal of Medicine · 2024 · 382 citations

Medicine, Oncology, Medical Oncology +6

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Silvia Novello, Julien Mazières, In‐Jae Oh et al. · Annals of Oncology · 2018 · 344 citations · Full text

Medicine, Oncology, Pharmacology +14

Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials

Myriam Chalabi, Andrés F. Cardona, Deepti R. Nagarkar et al. · Annals of Oncology · 2020 · 295 citations · Full text

Medicine, Oncology, Pharmacology +15